Fátima Nogueira

Fátima Nogueira  (https://www.cienciavitae.pt/7B1B-1ABB-1A16; ORCID iD 0000-0003-0313-0778, Scopus Author Id 7006748317) is Assistant Researcher at the Medical Parasitology Unit at IHMT-NOVA. Graduated in Microbial Biology and Genetics from the Faculty of Sciences of the University of Lisbon, in 1996, she obtained a Master’s degree in Medical Parasitology at IHMT-NOVA in 2001 and a PhD in Biomedical Sciences, specialty of Medical Parasitology at the same University in 2007.

The main research interests are the research mechanisms and therapeutic targets with respect to anti-malarial drugs; the development of molecular tools for monitoring anti-malarial-resistant malaria parasites and the search for synthetic and natural compounds as potential new anti-malarials.

More relevant projects at IHMT-NOVA:

• 2022.02426.PTDC; IRCNA/BRB/0281/2019_AMAZING; EuroNanoMed3-NANOpheles ref. 171129_ERA-Net_NANOpheles; COMPETE2020. SAICT/2019. REF:46871v; 2022.02426.PTDC; PTDC/MEDQUI/30021/2017; PTDC/BTM-SAL/29786/2017; PTDC/SAU-FAR/114864/2009 CRI and PTDC/QUI/65142/2006 and team member of EDCTP-RegNet2015-1049; Erasmus+ Programme. 586245-EPP-1-2017-1-FR-EPPKA2-CBHE-JP; PTDC/BIA-CEL/28456/2017; VIASEF FCT/P2020, FEDER.n.º2207 and PTDC/SAU-MET/110323/2009. CYTED REF: P215RT0054; CYTED REF: Red 210RT0398.

Author of 100 articles (73 SCOPUS) in international peer-reviewed journals in the areas of malaria pathology and anti-malarial resistance.

She has 2 patents:

• US20180186713 – Anti-malarial agent, methods and uses thereof;
• PAT356:P797.5US – WO2021/033159A1-PYRAZINO [1,2-B]QUINAZOLINE-3,6-DIONES, derivatives, their production and uses thereof.

Regularly maintains collaboration, training and field research activities in Africa with CPLP countries (Cape Verde, Angola and Mozambique), Brasil (FIOCRUZ/Farmanguinhos, BUTANTAN, UFPE e UFPB) and Senegal.

Member of the scientific committee of the PhD program in Tropical Diseases and Global Health at IHMT-NOVA.

She coordinates four curricular units (two in PhD and two in MSc) and teaches in two PhD programs and four Masters programs at IHMT-NOVA.

Supervisor of eleven doctoral students (four completed and seven in progress) and 26 master’s students (23 completed, three in progress).

Editor in Anti-Infective Agents section of Frontiers in Drug Design and in Discovery and Molecular Sciences: Molecular Pharmacology.

She is a member of RSTMH, from ASM and member of ASM Subcommittee for Career Development Grant for Postdoctoral Women (CDGPW).

Team: Ana Dias (P), Ana Cândido (ANG/P), Denise Duarte (P/BR), Daniela Matias (P), Celso Chaves (MZ), Clemente da Silva (MZ), Isabel Fonseca (P), Inês Morais (P), Mbueno Nzila (ANG), Valéria Chicamba (MZ).

1. Brown N, da Silva C, Webb C, Matias D, Dias B, Cancio B, Silva M, Viegas R, Salvador C, Chivale N, Luis S, Arnaldo P, Zulawinska J, Moore CC, Nogueira F, Guler JL. Antimalarial resistance risk in Mozambique detected by a novel quadruplex droplet digital PCR assay. Antimicrob Agents Chemother. 2024 Jul 9;68(7):e0034624. doi: 10.1128/aac.00346-24.  
2. Feitosa LM, Franca RRF, Ferreira MLG, Aguiar ACC, de Souza GE, Maluf SEC, de Souza JO, Zapata L, Duarte D, Morais I, Nogueira F, Nonato MC, Pinheiro LCS, Guido RVC, Boechat N. Discovery of new piperaquine hybrid analogs linked by triazolopyrimidine and pyrazolopyrimidine scaffolds with antiplasmodial and transmission blocking activities. Eur J Med Chem. 2024 Mar 5;267:116163. doi: 10.1016/j.ejmech.2024.116163. 
3. da Silva C, Matias D, Dias B, Cancio B, Silva M, Viegas R, Chivale N, Luis S, Salvador C, Duarte D, Arnaldo P, Enosse S, Nogueira F. Anti-malarial resistance in Mozambique: Absence of Plasmodium falciparum Kelch 13 (K13) propeller domain polymorphisms associated with resistance to artemisinins. Malar J. 2023 May 19;22(1):160. doi: 10.1186/s12936-023-04589-0.  
4. Ramos S, Ademolue TW, Jentho E, Wu Q, Guerra J, Martins R, Pires G, Weis S, Carlos AR, Mahú I, Seixas E, Duarte D, Rajas F, Cardoso S, Sousa AGG, Lilue J, Paixão T, Mithieux G, Nogueira F, Soares MP. A hypometabolic defense strategy against malaria. Cell Metab. 2022 Aug 2;34(8):1183-1200.e12. doi: 10.1016/j.cmet.2022.06.011.  
5. Silva-Pinto A, Domingos J, Cardoso M, Reis A, Benavente ED, Caldas JP, Conceição C, Toscano C, Baptista-Fernandes T, Clark TG, Mansinho K, Campino S, Nogueira F. Artemether-lumefantrine treatment failure of uncomplicated Plasmodium falciparum malaria in travellers coming from Angola and Mozambique. Int J Infect Dis. 2021 Sep;110:151-154. doi: 10.1016/j.ijid.2021.07.008.